NUS Cancer Immunotherapy Advance: PTP1B Molecular Target Drives Immunogenicity in New JACS Paper

Unlocking Cancer Cells' Immune Alert: NUS Researchers Pinpoint PTP1B as Key Trigger

In a landmark study published in the Journal of the American Chemical Society (JACS), scientists from the National University of Singapore (NUS) have uncovered a groundbreaking molecular mechanism that could supercharge cancer immunotherapy. Led by Professor Wee Han Ang from the NUS Department of Chemistry, the team identified protein tyrosine phosphatase 1B (PTP1B, full name Protein Tyrosine Phosphatase Non-Receptor Type 1) as a critical 'switch' regulating immunogenic cell death (ICD) in cancer cells. This discovery reveals how specific organoplatinum compounds can target PTP1B to make dying cancer cells scream for immune help, potentially transforming treatments for stubborn tumors like colorectal cancer.

Cancer immunotherapy harnesses the body's immune system to fight tumors, but many cancers evade detection by dying quietly without alerting T cells or dendritic cells. ICD changes that: it's a form of cell death where tumors release damage-associated molecular patterns (DAMPs)—signals like calreticulin on the surface, ATP, and HMGB1—that rally the immune army. The NUS work shows PTP1B normally suppresses these signals, acting as an intracellular checkpoint. By inhibiting it, therapies can flip the switch, turning 'cold' tumors hot and fostering long-lasting protection.

This isn't just lab theory. In mouse models of colorectal cancer, vaccination with cells treated by the compounds PlatinER (Pt-ER) and Pt-NHC led to 60% tumor-free survival upon rechallenge, far outperforming controls. Such results position PTP1B-targeted strategies at the forefront of chemoimmunotherapy, blending direct cell killing with adaptive immunity.

The Science Behind PTP1B: From Enzyme to Immunotherapy Game-Changer

PTP1B is an endoplasmic reticulum (ER)-resident enzyme that dephosphorylates tyrosine residues on proteins, fine-tuning signals like insulin response and cell adhesion. Prior research hinted at its role in cancer progression and T-cell exhaustion, but the NUS team first linked it directly to ICD. Using photoaffinity probes derived from Pt-ER—light-activated tags that 'stick' to targets—they pulled PTP1B out via proteomics (tandem mass tags quantitative analysis), confirming binding and inhibition with IC50 around 20 μM.

Step-by-step, here's how it unfolds: Platinum compounds enter cancer cells, bind PTP1B in the ER, block its activity. This sparks ER stress, activating the unfolded protein response (UPR) via PERK pathway. Calreticulin translocates to the surface (ecto-CRT increases 1.4-fold), promoting phagocytosis by immune cells. DAMPs flood out, priming dendritic cells to activate CD8+ T cells. In vivo, this cascade shrinks tumors and prevents recurrence.

Bioinformatics from public datasets (TCGA) showed PTPN1 (PTP1B gene) upregulated in colon tumors, correlating with poor survival and ER stress markers like PERK and IRE1α. In immune hotspots, it's high in B cells, suggesting broad regulatory power. For Singapore, where colorectal cancer ranks among top killers (over 2,000 new cases yearly per registry data), this hits home.

NUS Team's Innovative Methods: Proteomics Meets Precision Chemistry

The breakthrough stemmed from chemical ingenuity. Prof Ang's group designed photoactivable probes (P-1, P-2a/b, P-3) mimicking Pt-ER, retaining ICD hallmarks: phagocytosis boost, ecto-CRT exposure, HMGB1/ATP release. After UV crosslinking in cells, click chemistry enriched tagged proteins for tandem mass spectrometry. PTP1B topped hits (5-fold enrichment), validated by cellular thermal shift assay (CETSA)—compounds destabilized it thermally—and microscopy (colocalization r=0.9).

Genetic proof: siRNA knockdown of PTP1B mimicked effects, while PERK inhibitors blunted them. Pharmacological backups like DPM-1001 confirmed. This multi-pronged validation sets a gold standard for target ID in metal-based drugs, a niche where NUS excels. The paper graced JACS front cover, underscoring its impact (DOI: 10.1021/jacs.5c18904).

Collaborating with Assoc Prof Maria V. Babak at City University of Hong Kong brought proteomics prowess, highlighting Singapore-HK research synergy. For aspiring chemists eyeing oncology, NUS offers prime training grounds—check research jobs in Singapore universities.

Results That Reshape Tumor Immunity: From Cells to Mice

In colorectal cell lines (CT26), Pt-ER/Pt-NHC slashed viability while spiking ICD markers versus non-inducers. Phagocytosis by U937 macrophages rose dose-dependently; ecto-CRT hit 1.45-fold peaks. Vaccination: Mice injected dying treated cells rejected live tumors 60% of time (Pt-ER), matching doxorubicin benchmark.

Tumor rechallenge confirmed adaptive memory. PTP1B KO cells showed hyper-ICD; inhibitor combos amplified. No toxicity spikes, key for translation. These metrics—survival curves, growth kinetics—paint PTP1B as viable beyond platinum, perhaps for CAR-T boosts where prior studies showed it limits efficacy.

Singapore's cancer deaths dipped 21% since 2012 despite rising incidence (NCCS data), thanks to screening/immuno advances. Yet, immunotherapy response hovers 20-30% for solids; PTP1B could widen that net.

Singapore's Oncology Landscape: NUS Leads Amid Rising Challenges

Cancer claims 1 in 4 Singaporean lives; colorectal hits 1,800 new cases yearly (SCR 2023). Immunotherapy trials boom at NCIS (National Cancer Centre Singapore), with PD-1 inhibitors standard for MSI-high tumors. NUS's Centre for Cancer Research (N²CR) fuels this, hosting 2026 grant clinics and summits like NUHS Innovation Summit.

Prof Ang's lab builds on NUS strengths in medicinal chemistry, with RIE2025 injecting S$25B into biomed. Collaborations like Duke-NUS NCIS integrate discovery-to-clinic. PTP1B fits: ER stress ties to Asian-prevalent mutations. Regional context? SEA breast/colorectal surges; this exportable tech aids.

Expert Views: PTP1B as Next Checkpoint?

Prof Ang: “This links PTP1B to platinum ICD inducers' immune punch. Next: structural dynamics of PlatinER-PTP1B for optimized drugs.” Reviews affirm PTP1B curbs T-cell activation (Cancer Discovery 2022); inhibitors like MSI-1436 enhance CAR-T.

Stakeholders praise: Oncologists see synergy with anti-PD-1; chemists eye metal-PTP1B scaffolds. Challenges? Selectivity vs TC-PTP (homolog). Singapore's A*STAR trials could fast-track. For academics, NUS exemplifies translational impact—explore Singapore university opportunities.

Challenges, Solutions, and Road Ahead

Barriers: Platinum resistance, ICD variability across cancers. Solutions: PTP1B small-molecules (non-metal), combos with checkpoint blockers. Timelines: Structural studies 2026-27; IND filing 2028?

Real-world: Colorectal trials at NCIS; NUS N²CR seeds pilots. Actionable: Researchers, target PTP1B validation; patients, inquire ICD trials. Future: Personalized via PTPN1 expression.

Broad Impacts: Boosting Singapore's Biomed Edge

This elevates NUS globally (QS top 10 chemistry), drawing talent. Economic: Biomed hub generates 200K jobs. Patients gain hope—immuno survival leaped 70% globally 2026 (CRI stats).

Cultural: Singapore's merit-driven research culture shines. For profs/students, professor jobs abound in oncology.

Photo by National Institute of Allergy and Infectious Diseases on Unsplash

Conclusion: A New Era for Cancer Fighters

NUS's PTP1B revelation heralds smarter immunotherapy, merging chemistry and immunity. As trials advance, it promises fewer recurrences. Stay informed: Rate My Professor for insights, browse higher ed jobs, university jobs, or career advice. Post a role at /recruitment to attract top talent. Singapore leads—join the fight.

• Track NUS trials via NCIS.
• Researchers: Apply N²CR grants.
• Students: Pursue med chem at NUS.